

Nichole T Tanner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8985028/publications.pdf>

Version: 2024-02-01

62
papers

2,179
citations

236833

25
h-index

233338

45
g-index

62
all docs

62
docs citations

62
times ranked

2490
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 534-541. | 2.5 | 159 |
| 2 | Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy. Chest, 2019, 155, 137-146. | 0.4 | 150 |
| 3 | Management of Pulmonary Nodules by Community Pulmonologists. Chest, 2015, 148, 1405-1414. | 0.4 | 128 |
| 4 | Addressing Disparities in Lung Cancer Screening Eligibility and Healthcare Access. An Official American Thoracic Society Statement. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e95-e112. | 2.5 | 127 |
| 5 | Racial Differences in Outcomes within the National Lung Screening Trial. Implications for Widespread Implementation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 200-208. | 2.5 | 118 |
| 6 | Assessment of Plasma Proteomics Biomarkers' Ability to Distinguish Benign From Malignant Lung Nodules. Chest, 2018, 154, 491-500. | 0.4 | 114 |
| 7 | Primary Care Provider and Patient Perspectives on Lung Cancer Screening. A Qualitative Study. Annals of the American Thoracic Society, 2016, 13, 1977-1982. | 1.5 | 103 |
| 8 | Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival. Chest, 2017, 152, 587-597. | 0.4 | 95 |
| 9 | Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Chest, 2020, 158, 406-415. | 0.4 | 95 |
| 10 | Standard Bronchoscopy With Fluoroscopy vs Thin Bronchoscopy and Radial Endobronchial Ultrasound for Biopsy of Pulmonary Lesions. Chest, 2018, 154, 1035-1043. | 0.4 | 94 |
| 11 | Using Endobronchial Ultrasound Features to Predict Lymph Node Metastasis in Patients With Lung Cancer. Chest, 2011, 140, 1550-1556. | 0.4 | 91 |
| 12 | Physician Assessment of Pretest Probability of Malignancy and Adherence With Guidelines for Pulmonary Nodule Evaluation. Chest, 2017, 152, 263-270. | 0.4 | 85 |
| 13 | The Utility of Nodule Volume in the Context of Malignancy Prediction for Small Pulmonary Nodules. Chest, 2014, 145, 464-472. | 0.4 | 77 |
| 14 | Incorporating Coexisting Chronic Illness into Decisions about Patient Selection for Lung Cancer Screening. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e3-e13. | 2.5 | 63 |
| 15 | Attitudes and Beliefs Toward Lung Cancer Screening Among US Veterans. Chest, 2013, 144, 1783-1787. | 0.4 | 51 |
| 16 | Assessing the Generalizability of the National Lung Screening Trial: Comparison of Patients with Stage 1 Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 602-608. | 2.5 | 48 |
| 17 | Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest, 2018, 154, 110-118. | 0.4 | 46 |
| 18 | Evaluations of Implementation at Early-Adopting Lung Cancer Screening Programs. Chest, 2017, 152, 70-80. | 0.4 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | An Evaluation of Diagnostic Yield From Bronchoscopy. Chest, 2020, 157, 1656-1664. | 0.4 | 42 |
| 20 | Shared Decision-making and Lung Cancer Screening. Chest, 2019, 155, 21-24. | 0.4 | 38 |
| 21 | Screening Adherence in the Veterans Administration Lung Cancer Screening Demonstration Project. Chest, 2020, 158, 1742-1752. | 0.4 | 38 |
| 22 | Guideline-Recommended Lung Cancer Screening Adherence Is Superior With a Centralized Approach. Chest, 2022, 161, 818-825. | 0.4 | 37 |
| 23 | Training for Linear Endobronchial Ultrasound Among US Pulmonary/Critical Care Fellowships. Chest, 2013, 143, 423-428. | 0.4 | 33 |
| 24 | Assessing the Usefulness of 18 F-fluorodeoxyglucose PET-CT Scan After Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer. Chest, 2014, 146, 406-411. | 0.4 | 33 |
| 25 | The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer, 2012, 76, 131-137. | 0.9 | 26 |
| 26 | Physician Preferences for Management of Patients with Stage IIIA NSCLC: Impact of Bulk of Nodal Disease on Therapy Selection. Journal of Thoracic Oncology, 2012, 7, 365-369. | 0.5 | 25 |
| 27 | In-person and Telephonic Shared Decision-making Visits for People Considering Lung Cancer Screening. Chest, 2019, 155, 236-238. | 0.4 | 23 |
| 28 | Reviewing Lung Cancer Screening. Clinics in Chest Medicine, 2018, 39, 31-43. | 0.8 | 17 |
| 29 | Management of Lung Nodules and Lung Cancer Screening During the COVID-19 Pandemic. Journal of the American College of Radiology, 2020, 17, 845-854. | 0.9 | 17 |
| 30 | Comparing Pulmonary Nodule Location During Electromagnetic Bronchoscopy With Predicted Location on the Basis of Two Virtual Airway Maps at Different Phases of Respiration. Chest, 2018, 153, 181-186. | 0.4 | 16 |
| 31 | Utilizing Endobronchial Ultrasound With Fine-Needle Aspiration to Obtain Tissue for Molecular Analysis. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 317-321. | 0.8 | 14 |
| 32 | Approaches to lung nodule risk assessment: clinician intuition versus prediction models. Journal of Thoracic Disease, 2020, 12, 3296-3302. | 0.6 | 12 |
| 33 | Diagnostic Approach to the Solitary Pulmonary Nodule. Seminars in Respiratory and Critical Care Medicine, 2013, 34, 762-769. | 0.8 | 11 |
| 34 | Biomarkers in the selection of maintenance therapy in non-small cell lung cancer. Translational Lung Cancer Research, 2012, 1, 96-8. | 1.3 | 10 |
| 35 | EGFR mutations in malignant pleural effusions from lung cancer. Current Respiratory Care Reports, 2013, 2, 79-87. | 0.6 | 9 |
| 36 | Assessment of Integrated Classifier's Ability to Distinguish Benign From Malignant Lung Nodules. Chest, 2021, 159, 1283-1287. | 0.4 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Tobacco Treatment Specialist Training for Lung Cancer Screening Providers. American Journal of Preventive Medicine, 2021, 61, 765-768. | 1.6 | 7 |
| 38 | Simultaneously Diagnosing and Staging Lung Cancer. Chest, 2013, 144, 1747-1749. | 0.4 | 6 |
| 39 | Association of Cigarette Type and Nicotine Dependence in Patients Presenting for Lung Cancer Screening. Chest, 2020, 158, 2184-2191. | 0.4 | 6 |
| 40 | Lung Cancer Screening. Clinics in Chest Medicine, 2020, 41, 87-97. | 0.8 | 6 |
| 41 | A 79-Year-Old Woman With a Right Paratracheal Mass. Chest, 2009, 135, 1384-1388. | 0.4 | 5 |
| 42 | Convex Probe Endobronchial Ultrasound. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 636-644. | 0.8 | 5 |
| 43 | Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons. Clinical Lung Cancer, 2020, 21, e89-e98. | 1.1 | 5 |
| 44 | Mediastinal Staging for Lung Cancer. Chest, 2021, 160, 1552-1559. | 0.4 | 5 |
| 45 | New testing for lung cancer screening. Oncology, 2012, 26, 176-82. | 0.4 | 5 |
| 46 | An up to date look at lung cancer screening. Cell Adhesion and Migration, 2010, 4, 96-99. | 1.1 | 4 |
| 47 | POINT: Is N2 Disease a Contraindication for Surgical Resection for Superior Sulcus Tumors? Yes. Chest, 2015, 148, 1373-1375. | 0.4 | 4 |
| 48 | Screening for Lung Cancer Using Low-Dose Computed Tomography. Are We Headed for DANTE's Paradise or Inferno?. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1100-1101. | 2.5 | 4 |
| 49 | An Evaluation of Annual Adherence to Lung Cancer Screening in a Large National Cohort. American Journal of Preventive Medicine, 2022, 63, e59-e64. | 1.6 | 4 |
| 50 | What's in a Number? When It Comes to Pulmonary Nodules, It's All About the Number. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1149-1150. | 2.5 | 3 |
| 51 | Lung cancer screening at the VA: Past, present and future. Seminars in Oncology, 2022, 49, 206-212. | 0.8 | 3 |
| 52 | Denture Misadventure. Journal of Bronchology and Interventional Pulmonology, 2009, 16, 216-218. | 0.8 | 2 |
| 53 | Chronic Obstructive Pulmonary Disease as a Lung Cancer Risk: Worth Its Weight in "GOLD". Annals of the American Thoracic Society, 2017, 14, 309-310. | 1.5 | 2 |
| 54 | Safely and Effectively Evaluating Computed Tomography-detected Lung Lesions. Much Work to Be Done. Annals of the American Thoracic Society, 2019, 16, 1360-1362. | 1.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Impact of Tobacco Dependence in Risk Prediction Models for Lung Cancer Diagnoses and Deaths. JNCI Cancer Spectrum, 2019, 3, pkz014. | 1.4 | 2 |
| 56 | Occurrence of Discussion about Lung Cancer Screening Between Patients and Healthcare Providers in the USA, 2017. Journal of Cancer Education, 2020, 35, 678-681. | 0.6 | 2 |
| 57 | Lung Cancer Screening: Adjuncts and Alternatives to Low-Dose CT Scans. Current Surgery Reports, 2013, 1, 249-256. | 0.4 | 0 |
| 58 | ATS Core Curriculum 2017: Part IV. Adult Pulmonary Medicine. Annals of the American Thoracic Society, 2017, 14, S196-S208. | 1.5 | 0 |
| 59 | Response. Chest, 2017, 152, 448-449. | 0.4 | 0 |
| 60 | Improving Inequities in Lung Cancer Screening: Risk Prediction Models and the Potential to Achieve a Great Equalizer Effect. Journal of Thoracic Oncology, 2020, 15, 1711-1713. | 0.5 | 0 |
| 61 | Response. Chest, 2021, 159, 438-439. | 0.4 | 0 |
| 62 | Response. Chest, 2021, 159, 2122. | 0.4 | 0 |